OvaScience (NASDAQ: CBIO) and Catalyst Biosciences (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.
Earnings and Valuation
This table compares OvaScience and Catalyst Biosciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Catalyst Biosciences||$1.02 million||129.82||-$21.56 million||($7.45)||-1.49|
This is a breakdown of current ratings and recommmendations for OvaScience and Catalyst Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OvaScience currently has a consensus target price of $15.00, indicating a potential upside of 1,873.68%. Catalyst Biosciences has a consensus target price of $23.75, indicating a potential upside of 114.16%. Given OvaScience’s stronger consensus rating and higher probable upside, equities research analysts plainly believe OvaScience is more favorable than Catalyst Biosciences.
Volatility and Risk
OvaScience has a beta of 3.34, indicating that its stock price is 234% more volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500.
This table compares OvaScience and Catalyst Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
20.6% of OvaScience shares are held by institutional investors. Comparatively, 69.2% of Catalyst Biosciences shares are held by institutional investors. 7.4% of OvaScience shares are held by company insiders. Comparatively, 3.1% of Catalyst Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Catalyst Biosciences beats OvaScience on 7 of the 13 factors compared between the two stocks.
OvaScience, Inc., a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide. Its patented technology is based on the discovery about the existence of egg precursor (EggPC) cells to transform the treatment landscape for women's fertility. The company offers various fertility treatment options, including OvaPrime treatment to restore a woman's egg production by isolating a woman's own EggPC cells within her ovary to mature in vivo into healthy and fertilizable eggs; OvaTure treatment to mature EggPC cells into fertilizable eggs in vitro or outside the body by eliminating the need for hormone stimulation; and AUGMENT treatment to enhance the fertilization and pregnancy rates by using mitochondria from a woman's own EggPC cells. It also provides OvaXon for the prevention of inherited diseases for human and animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
About Catalyst Biosciences
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing CB 2679d/ISU304, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company is headquartered in South San Francisco, California.
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.